Dianthus Therapeutics, Inc. (DNTH) stock
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$83.98−3.00 (-3.45%)
Close on Nov 18, 2026Market cap $4.70BP/E –Yield 0.00%
Dianthus Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Dianthus Therapeutics's free cash flow for the twelve months ending Jun 30, 2023 was -$7.89M. For fiscal 2022 it was -$29.38M. The highest annual figure on record is -$6.67M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$29.38M | – |
| FY2021 | Dec 31, 2021 | -$60.80M | – |
| FY2020 | Dec 31, 2020 | -$64.42M | – |
| FY2019 | Dec 31, 2019 | -$60.16M | – |
| FY2018 | Dec 31, 2018 | -$49.56M | – |
| FY2017 | Dec 31, 2017 | -$24.46M | – |
| FY2016 | Dec 31, 2016 | -$6.67M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$4.73M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.85M | – |
| Q3 FY2022 | Sep 30, 2022 | $16.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.11M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.78M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.95M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.24M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.78M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.16M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.19M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.79M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.55M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.83M | – |
See a number that looks wrong?